Profilo
Konrad Glund is the founder of Vivoryon Therapeutics NV, which was founded in 1997.
He held the title of Chief Executive Officer from 2006 to 2018.
Dr. Glund is also the founder of IFB Halle GmbH.
He previously worked as Vice President-Corporate Development at Prosidion Ltd. and as a Principal at Martin-Luther-Universität Halle-Wittenberg.
Dr. Glund earned a doctorate degree from Martin-Luther-Universität Halle-Wittenberg.
Precedenti posizioni note di Konrad Glund
| Società | Posizione | Fine |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Amministratore Delegato | 30/04/2018 |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Manufactures products for treatment of metabolic diseases | Corporate Officer/Principal | - |
Martin-Luther-Universität Halle-Wittenberg
Martin-Luther-Universität Halle-Wittenberg Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
IFB Halle GmbH | Amministratore Delegato | - |
Formazione di Konrad Glund
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Manufactures products for treatment of metabolic diseases | Health Technology |
Vivoryon Therapeutics NV
Vivoryon Therapeutics NV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that is engaged in the research and development of new therapeutic products for the treatment of Alzheimer disease | Commercial Services |
Martin-Luther-Universität Halle-Wittenberg
Martin-Luther-Universität Halle-Wittenberg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IFB Halle GmbH |
















